aHUS News

aHUS News is a digital resource designed to keep the atypical hemolytic uremic syndrome (aHUS) community updated with the latest news and insights. It also features personal stories and viewpoints from our patient and caregiver contributors. Every article on aHUS News is created by our dedicated team of writers and editors. From time to time, we invite external experts to share their knowledge through interviews and Q&A sessions. Our publishing team consists of science writers and editors, many of whom hold PhDs in life sciences, along with experienced journalists and columnists who are part of the AADC community. Together, they strive to ensure that all content on aHUS News is accurate, relevant, informative, and easy to understand for our readers.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#4878230

United States

#1407858

Articles

Plasma exchange therapy, Soliris manage aHUS in boy: Report

1 week ago | ahusnews.com | Marisa Wexler

Plasma exchange therapy followed by treatment with Soliris (eculizumab) was effective at managing atypical hemolytic uremic syndrome (aHUS) in a boy in China. The case was described in the report, " Plasma exchange combined with eculizumab in the management of atypical hemolytic uremic in pediatric patients: A case report ," which was published in Medicine.
Epysqli, Soliris biosimilar, now available for aHUS patients in US

2 weeks ago | ahusnews.com | Marisa Wexler

Epysqli (eculizumab-aagh), a biosimilar of Soliris (eculizumab), is now available for patients in the U.S., according to an announcement from Samsung Bioepis and Teva Pharmaceuticals. The biosimilar is authorized to treat people with atypical hemolytic uremic syndrome (aHUS), as well as paroxysmal nocturnal hemoglobinuria, and generalized myasthenia gravis - all of which are conditions that Soliris is approved to treat.
Woman with lupus developed aHUS after pregnancy in rare case

3 weeks ago | ahusnews.com | Marisa Wexler

A woman with lupus in her early 30s, who developed atypical hemolytic uremic syndrome (aHUS) after pregnancy, was not suspected of having the rare condition until five days after her baby's birth, which resulted in her not receiving the correct treatment, according to a case report from researchers in Japan. "In this case, delayed recognition of aHUS precluded the use of [appropriate] therapies," the researchers wrote.
Report aims to help distinguish aHUS disease vs. HELLP syndrome

1 month ago | ahusnews.com | Margarida Maia

The pregnancy-related complication HELLP syndrome - fully known as hemolysis, elevated liver enzymes, and low platelets syndrome, which causes high blood pressure and organ damage - is sometimes confused with atypical hemolytic uremic syndrome, or aHUS, a rare disease in which kidney dysfunction persists for a long time, especially when the complication occurs before or after a woman gives birth.
Soliris lowers kidney risks from pregnancy-associated aHUS: Study

1 month ago | ahusnews.com | Margarida Maia

Soliris (eculizumab) largely reduces the risk of long-term kidney problems in women who develop atypical hemolytic uremic syndrome (aHUS) during or after pregnancy, a meta-analysis study has found. "This analysis highlights the severe kidney and pregnancy outcomes associated with [pregnancy-associated aHUS]," researchers wrote, noting Soliris treatment is beneficial for reducing the risk of chronic and end-stage kidney disease.
Interactive e-book aims to help children better understand aHUS

2 months ago | ahusnews.com | Lindsey Shapiro

An interactive electronic storybook, or e-book, designed to help children with atypical hemolytic uremic syndrome (aHUS) better understand their rare disease, has been launched by Alexion, AstraZeneca Rare Disease, which markets two aHUS therapies. Called " Revealing the Secrets of aHUS," the fantasy e-book uses imaginative play to educate children and provide clarity about aHUS in ways that are fun and engaging - and appropriate for young children.
Pregnant woman diagnosed with aHUS after being induced early

2 months ago | ahusnews.com | Patricia Inacio

Timely diagnosis and aggressive treatment were crucial for the recovery of a 26-year-old woman who was diagnosed with atypical hemolytic uremic syndrome (aHUS) after she was induced at 30 weeks of pregnancy, researchers in China report. "Clinical data and treatment experiences related to pregnancy-associated aHUS remain limited. This case report highlights the importance of prompt identification and management of aHUS," researchers wrote.
COVID-19 triggers aHUS in boy, 13, case report details

2 months ago | ahusnews.com | Patricia Inacio

COVID-19 triggered atypical hemolytic uremic syndrome (aHUS) in a 13-year-old boy with a genetic predisposition to the syndrome, a recent case study reports. Treatment with plasma exchange therapy, a type of blood-cleansing procedure, was effective, and the boy fully recovered. "This case highlights the potential of COVID-19 to trigger aHUS, particularly in individuals with underlying genetic predispositions," the researchers wrote.
Teva gets US marketing rights in AHUS for Soliris biosimilar Epysqli

Jan 15, 2025 | ahusnews.com | Patricia Inacio

Under a new commercialization agreement with Samsung Bioepis, the developer of Epysqli (eculizumab-aagh), Teva Pharmaceuticals will have exclusive marketing rights in the U.S. for the Soliris (eculizumab) biosimilar - an approved treatment for atypical hemolytic uremic syndrome (aHUS). A biosimilar is a biological product that is highly similar to an already approved biological medicine.
C5 inhibitor found best to regain postpartum aHUS kidney function

Jan 8, 2025 | ahusnews.com | Margarida Maia

The use of a C5 inhibitor - with or without plasma exchange - was found to work better than supportive care to treat kidney problems in women who develop atypical hemolytic uremic syndrome (aHUS) as a complication of bleeding after giving birth, a study found.